KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Other Working Capital Changes (2016 - 2025)

TherapeuticsMD's Other Working Capital Changes history spans 16 years, with the latest figure at -$788000.0 for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 18.68% year-over-year to -$788000.0; the TTM value through Dec 2025 reached -$1.6 million, down 63.9%, while the annual FY2025 figure was $19000.0, 26.67% up from the prior year.
  • Other Working Capital Changes reached -$788000.0 in Q4 2025 per TXMD's latest filing, down from $6000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $1.5 million in Q1 2023 to a low of -$1.9 million in Q2 2023.
  • Average Other Working Capital Changes over 5 years is -$27300.0, with a median of $6000.0 recorded in 2025.
  • The largest YoY upside for Other Working Capital Changes was 20857.14% in 2023 against a maximum downside of 2117.89% in 2023.
  • A 5-year view of Other Working Capital Changes shows it stood at -$6000.0 in 2021, then plummeted by 150.0% to -$15000.0 in 2022, then soared by 1153.33% to $158000.0 in 2023, then crashed by 713.29% to -$969000.0 in 2024, then increased by 18.68% to -$788000.0 in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Other Working Capital Changes are -$788000.0 (Q4 2025), $6000.0 (Q3 2025), and $6000.0 (Q2 2025).